CLEVELAND--(BUSINESS WIRE)--Neuros Medical, Inc., a medical device company announced it has received an Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration allowing it to commence a pilot clinical trial to evaluate the Company’s patented high frequency Electrical Nerve Block™ technology for use in acute treatment of pain in the residual limb of amputees. The IDE approval builds off of the Company’s successful first-in-man feasibility study earlier this year, in which four out of five patients reported significant pain reduction, at times reducing pain scores to zero. The feasibility study was the first human test of the Company’s high frequency Electrical Nerve Block technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S.
